Lecanemab — complimentary MARA Rating report cover: pricing & reimbursement risk assessment for early Alzheimer’s disease.
The complimentary MARA Rating® report evaluates Lecanemab’s market access prospects for the treatment of early Alzheimer’s disease. The overall outcome assigns the therapy a MARA Score of 2.7 out of 4, classified as B++ (Marginal). For context, the 5-year average in neurology is 2.9 and the broader industry average is 3.0, positioning Lecanemab slightly below both benchmarks.
Clinical Effectiveness: A (Strong)
Findings from the Phase 3 _Clarity AD_ trial showed that Lecanemab slowed cognitive decline by 27% compared with placebo over 18 months, as measured by the CDR-SB scale. The absolute difference of 0.45 points indicates statistical significance, but questions remain about the clinical relevance since no patients showed cognitive improvement. Overall, the therapy demonstrates a modest but verifiable benefit against standard care.
Comparator Selection: A++ (Excellent)
The pivotal trial used placebo plus standard care as the comparator, which is considered fully appropriate given the absence of alternative disease-modifying options for early Alzheimer’s disease. This choice ensures that efficacy results are both relevant and applicable to current clinical settings.
Care-Pathway Integration: B++ (Marginal)
Successful adoption would require considerable adaptations, such as biomarker testing and close monitoring for amyloid-related imaging abnormalities (ARIA). These additional requirements represent a significant departure from existing practices and could strain healthcare system resources and training capacity.
About MARA Rating®
The MARA Rating synthesizes ten dimensions of market access risk—clinical efficacy, health-economic value, safety profile, comparator robustness, budget impact, and more—each scored on a seven-level scale (A++ to C). We then apply evidence-based weightings to generate a single risk score. A high MARA Score (A to A++) signals strong access prospects; a low score (B++ to C) denotes elevated pricing and potential reimbursement hurdles.
Unlock Premium Insights
Explore seven additional domains: Quality of Life (HRQoL), Cost-Effectiveness, Safety, Patient Population, Resource Use & Cost Implications, Evidence Quality, and Uncertainty. Available exclusively in Premium Insights at mararating.com.
Full Premium Report available upon request: Visit mararating.com or email at sales@mararating.com to learn more and unlock your access.
Disclaimer: The MARA Rating® is an independent opinion of a drug’s market-access risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. See our full disclaimer in mararating.com
More information: https://mararating.com/donanemab-mara-market-access-rating-for-alzheimers-disease/
Other diseases: https://mararating.com/report/filgrastim-for-the-treatment-of-severe-chronic-neutropenia-as-of-august-2025/
Access this report and hundreds of others here: https://mararating.com/mara-ratings-list.